SecBot SecBot
Biotech Drug Report Generated Nov 10, 2026

AB-101

ABUS·Arbutus Biopharma Corporation
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 1a/1b
Time to market
AB-101 is in Phase 1a/1b trials; even if development proceeds smoothly, a potential approval is likely several years away given the early stage and the need for larger Phase 2 and Phase 3 trials.
Why 4/10
AB-101 has no hard dated catalyst (PDUFA, pivotal readout, or AdComm) scheduled in the next ~12 months. The clinical hold was lifted on October 22, 2026, but the company is still evaluating next steps for clinical development. As an early-stage (Phase 1a/1b) asset at a company with other pipeline programs (imdusiran is more advanced), the impact score defaults to 4.
Actionable Insight NEUTRAL

The next catalyst for ABUS is Q3 2026 earnings on November 11, 2026 (tomorrow), which may include updates on AB-101's clinical development plans now that the FDA hold is lifted. For AB-101 specifically, watch for the company to announce the next phase of clinical trials in chronic hepatitis B patients. The clinical hold lift removes a key overhang, but the drug remains early-stage with no pivotal readout or PDUFA date on the horizon.

Price Chart

Loading chart...

Executive Summary

AB-101 is an oral small-molecule PD-L1 inhibitor in Phase 1a/1b clinical development by Arbutus Biopharma Corp (NASDAQ: ABUS) for chronic hepatitis B virus (HBV) infection. On October 22, 2026, the FDA lifted a clinical hold on AB-101's IND, allowing U.S. clinical development to resume. Early data from the AB-101-001 trial presented at AASLD 2025 showed the drug was well tolerated up to 30mg daily for 28 days in chronic HBV patients, with 83% mean maximal PD-L1 receptor occupancy at the 30mg dose. The company is still evaluating next steps for the program. AB-101 is one of two key HBV assets at Arbutus, alongside the more advanced RNAi therapeutic imdusiran (Phase 2a). The stock trades at $3.72 near its 52-week low, with a market cap supported by a recent $178M Moderna patent settlement and $230M share buyback.

How It Works

AB-101 is an oral (pill) small molecule that blocks the PD-L1 protein. PD-L1 is a 'brake' that cancer cells and virus-infected cells use to hide from the immune system. By blocking PD-L1, AB-101 releases this brake, allowing the body's T-cells to recognize and attack liver cells infected with hepatitis B virus. Unlike injected PD-1/PD-L1 inhibitors used in cancer, AB-101 is taken by mouth, which could make it more convenient for chronic hepatitis B patients who need long-term treatment.

Trial Status

AB-101 is being studied in the Phase 1a/1b AB-101-001 trial. Part 3 data in chronic HBV patients showed once-daily 10mg dosing for 28 days was well tolerated with PD-L1 receptor occupancy similar to healthy volunteers. Data presented at AASLD 2025 showed doses up to 30mg QD for 28 days were generally well tolerated, with 83% mean maximal PD-L1 receptor occupancy at 30mg. The FDA clinical hold was lifted on October 22, 2026, and the company is evaluating next steps for clinical development.

The Two-Sided Case

▲ Bull Case5
The FDA clinical hold on AB-101's IND was lifted on October 22, 2026, a positive regulatory de-risking event that allows U.S. clinical development to resume.
Phase 1a/1b data presented at AASLD 2025 showed AB-101 was well tolerated up to 30mg QD for 28 days in chronic HBV patients, with 83% mean maximal PD-L1 receptor occupancy at the 30mg dose, suggesting target engagement.
AB-101 is an oral small-molecule PD-L1 inhibitor, a novel approach for chronic HBV that could restore T-cell function against infected liver cells, potentially as part of a functional cure combination.
Arbutus has a strong cash position following a $178M Moderna patent settlement and completed a $230M share buyback, signaling management confidence and reducing share count by ~23%.
Analyst consensus shows 3 Strong Buy and 3 Buy ratings (vs 1 Hold, 0 Sell), with a mean price target of $5.40, implying roughly 45% upside from the current $3.72 price.
▼ Bear Case5
AB-101 is still in Phase 1a/1b, an early stage with a high risk of failure in later trials; many drug candidates fail to show efficacy in Phase 2.
The clinical hold was only recently lifted (October 22, 2026), and the company is still evaluating next steps, meaning there is no clear timeline for advancing the program.
Arbutus has no approved products and remains a clinical-stage biotech; the stock trades near its 52-week low of $3.50, reflecting ongoing execution risk.
Competition in the chronic hepatitis B space is intense, with multiple approaches including RNAi therapeutics (Arbutus's own imdusiran), antisense, and oral antivirals from larger players.
The company's quant composite score is just 2 out of 100, with negative 1-month (-11.85%), 3-month (-20.34%), and 6-month (-15.26%) returns, indicating weak recent momentum.

Upcoming Catalysts

  • Q3 2026 earnings call on November 11, 2026, which may include updates on AB-101's clinical development plans
  • Announcement of next clinical trial design and timeline for AB-101 now that the FDA hold is lifted

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Arbutus Biopharma Corporation PRESS-RELEASE ABUS ·Originating report

Sources · 9

Hover a chip for the title
1 markets.businessinsider.com2 streetinsider.com3 markets.financialcontent.com4 streetinsider.com5 seekingalpha.com6 marketscreener.com7 msn.com8 keloland.com9 sec.gov